Intranasal esketamine use in bipolar disorder: A case report
Over the past few years, intranasal esketamine has been FDA-approved for treatment-resistant depression as well as MDD with suicidal ideation. In the clinical trials leading to the recent FDA approvals, subjects with a diagnosis of bipolar disorder were excluded from participation in the trial. The...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Allen Press Inc.
2021
|
| Subjects: | |
| Online Access: | View Fulltext in Publisher |